Challenges in Europe include the impact of ageing populations on health systems, the spread of chronic diseases and budget pressures resulting from the economic context.

The traditional model for healthcare delivery is therefore being reconsidered. Regulators at an EU and national level are working hard to navigate the transition to a more decentralised and technology driven healthcare provision.

Within this shifting framework, pharmaceutical companies, health service providers and patient organisations (amongst others), must work to maintain their clinical standing while offering new solutions to meet the changing demands of regulators and health services.